Exelixis | EXEL - Zinsaufwendungen Für Schuld

Aktienkurs
44.94
Täglich Wechseln
-1.11 -2.41%
Monatlich
5.04%
Jährlich
20.06%
Q2 Prognose
43.98




Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Akebia Therapeutics 4.83M 359.32M 2025-12
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
Bayer EUR 675M 87M 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Cytokinetics USD 30.33M 4.01M 2025-12
Eisai JPY 1.43B 12M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Genmab DKK 10M 27M 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 582K 10K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Sanofi EUR -25M 99.78M 2025-12
Takeda JPY 123.63B 40.49B 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Xencor USD 7.35M 311K 2025-12